Trials / Completed
CompletedNCT02436928
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Medigen Vaccine Biologics Corp. · Industry
- Sex
- All
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AT-501 High Dose vaccine | Comparison of each dose of vaccine |
| BIOLOGICAL | AT-501 High Dose vaccine with Adjuvant | Comparison of each dose of vaccine |
| BIOLOGICAL | AT-501 Low Dose vaccine | Comparison of each dose of vaccine |
| BIOLOGICAL | AT-501 Low Dose vaccine with Adjuvant | Comparison of each dose of vaccine |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2015-05-07
- Last updated
- 2016-08-22
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02436928. Inclusion in this directory is not an endorsement.